Humacyte Prices $50M Public Offering at $1.05, Below Market Price
HUMA has more than doubled off its 52-week low of $0.547.
Summary
Humacyte priced a $50 million public offering of 47.6 million common shares at $1.05 per share, a discount to its current trading price. This significant capital raise, representing over 16% of the company's market capitalization, will be dilutive for existing shareholders. The offering follows yesterday's positive Phase 3 clinical trial results and recent shareholder approval to increase authorized shares, providing funds for Symvess commercialization and pipeline development. This continues a pattern of dilutive financing for the company, which previously issued a "going concern" warning. The offering is expected to close around June 12, 2026.
At the time of this announcement, HUMA was trading at $1.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $297.5M. The 52-week trading range was $0.55 to $2.84. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.